Nathalie Largeron

1.4k total citations
64 papers, 1.1k citations indexed

About

Nathalie Largeron is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Nathalie Largeron has authored 64 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Epidemiology, 16 papers in Infectious Diseases and 16 papers in Health. Recurrent topics in Nathalie Largeron's work include Cervical Cancer and HPV Research (28 papers), Hepatitis B Virus Studies (19 papers) and Vaccine Coverage and Hesitancy (16 papers). Nathalie Largeron is often cited by papers focused on Cervical Cancer and HPV Research (28 papers), Hepatitis B Virus Studies (19 papers) and Vaccine Coverage and Hesitancy (16 papers). Nathalie Largeron collaborates with scholars based in France, United Kingdom and Italy. Nathalie Largeron's co-authors include Vanessa Rémy, Xavier Bresse, M. Uhart, Sibilia Quilici, Stève Bénard, Stuart Carroll, Paolo Giorgi Rossi, Stéphane Roze, Ruanne V. Barnabas and Shalini Kulasingam and has published in prestigious journals such as BMC Public Health, Vaccine and Gynecologic Oncology.

In The Last Decade

Nathalie Largeron

61 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathalie Largeron France 20 809 293 255 207 154 64 1.1k
Vanessa Rémy France 15 435 0.5× 288 1.0× 151 0.6× 183 0.9× 75 0.5× 20 739
Michele Kohli United States 13 714 0.9× 184 0.6× 319 1.3× 122 0.6× 145 0.9× 31 1.2k
Sarah Reagan-Steiner United States 11 1.0k 1.2× 514 1.8× 283 1.1× 477 2.3× 181 1.2× 23 1.6k
Géraldine Dominiak-Felden France 9 690 0.9× 114 0.4× 359 1.4× 83 0.4× 113 0.7× 9 838
Angela Guo United States 11 717 0.9× 163 0.6× 33 0.1× 166 0.8× 48 0.3× 27 974
W. John Edmunds United Kingdom 15 1.0k 1.2× 94 0.3× 148 0.6× 169 0.8× 82 0.5× 22 1.4k
Barbara A. Slade United States 18 820 1.0× 395 1.3× 196 0.8× 387 1.9× 41 0.3× 25 1.6k
Yi Luo United States 18 770 1.0× 286 1.0× 49 0.2× 686 3.3× 47 0.3× 72 1.5k
Benjamin M. Kagina South Africa 20 637 0.8× 284 1.0× 125 0.5× 736 3.6× 39 0.3× 60 1.3k
B. Ultsch Germany 18 527 0.7× 138 0.5× 88 0.3× 88 0.4× 16 0.1× 48 782

Countries citing papers authored by Nathalie Largeron

Since Specialization
Citations

This map shows the geographic impact of Nathalie Largeron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathalie Largeron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathalie Largeron more than expected).

Fields of papers citing papers by Nathalie Largeron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathalie Largeron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathalie Largeron. The network helps show where Nathalie Largeron may publish in the future.

Co-authorship network of co-authors of Nathalie Largeron

This figure shows the co-authorship network connecting the top 25 collaborators of Nathalie Largeron. A scholar is included among the top collaborators of Nathalie Largeron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathalie Largeron. Nathalie Largeron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Graham, Charlotte, et al.. (2025). Opportunities for and Challenges of Conducting Indirect Treatment Comparisons and Meta-Analyses for Vaccines in Post-EU HTA Regulation Era. Journal of Market Access & Health Policy. 13(2). 31–31.
2.
3.
4.
5.
6.
Joura, Elmar A., et al.. (2016). Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infectious Diseases. 16(1). 153–153. 40 indexed citations
7.
Joura, Elmar A., et al.. (2015). Estimating The Cost-Effectiveness Profile of A Universal Vaccination Programme With A Nine-Valent Hpv Vaccine In Austria. Value in Health. 18(7). A585–A585. 3 indexed citations
8.
Uhart, M., et al.. (2015). Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Human Vaccines & Immunotherapeutics. 11(4). 884–896. 15 indexed citations
9.
Mennini, F.S., F. Bianic, Gianluca Baio, et al.. (2015). Estimating The Cost-Effectiveness Profile Of A Vaccination Programme With A Nine-Valent Hpv Vaccine In Italy. Value in Health. 18(7). A457–A457. 2 indexed citations
10.
11.
Marsh, Kevin, Ruth Chapman, Rebecca F. Baggaley, Nathalie Largeron, & Xavier Bresse. (2014). Mind the gaps: What's missing from current economic evaluations of universal HPV vaccination?. Vaccine. 32(30). 3732–3739. 18 indexed citations
12.
Kawai, Kosuke, et al.. (2014). Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 32(15). 1645–1653. 40 indexed citations
13.
Postma, Maarten J., Tjalke A. Westra, Sibilia Quilici, & Nathalie Largeron. (2013). Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples. Expert Review of Vaccines. 12(5). 555–565. 9 indexed citations
14.
Rémy, Vanessa, Patrice Mathevet, Nathalie Largeron, & Alexandre Vainchtock. (2010). Coût de prise en charge des cancers de la vulve et du vagin en France. 28(1). 31–31. 2 indexed citations
15.
Littlewood, Kavi J., et al.. (2010). Cost–effectiveness of catch-up programs in human papillomavirus vaccination. Expert Review of Vaccines. 9(10). 1187–1201. 5 indexed citations
16.
Kulasingam, Shalini, Stève Bénard, Ruanne V. Barnabas, Nathalie Largeron, & Evan R. Myers. (2008). Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Effectiveness and Resource Allocation. 6(1). 4–4. 73 indexed citations
17.
Largeron, Nathalie, et al.. (2008). Burden of rotavirus gastroenteritis and potential benefits of a pentavalent rotavirus vaccination in Belgium. Journal of Medical Economics. 11(3). 431–448. 6 indexed citations
18.
Bergeron, Christine, et al.. (2008). Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International Journal of Technology Assessment in Health Care. 24(1). 10–19. 71 indexed citations
19.
Huet, Frédéric, et al.. (2008). Évaluation du coût de la prise en charge pédiatrique des gastroentérites aiguës à rotavirus. Archives de Pédiatrie. 15(7). 1159–1166. 5 indexed citations
20.
Largeron, Nathalie, et al.. (2007). PG13 BUDGET IMPACT OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAMME WITH ROTATEQ® IN FRANCE. Value in Health. 10(6). A352–A352. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vanessa Rémy Breakdown of academic impact, for papers by Michele Kohli Breakdown of academic impact, for papers by Sarah Reagan-Steiner Breakdown of academic impact, for papers by Géraldine Dominiak-Felden Breakdown of academic impact, for papers by Angela Guo Breakdown of academic impact, for papers by W. John Edmunds Breakdown of academic impact, for papers by Barbara A. Slade Breakdown of academic impact, for papers by Yi Luo Breakdown of academic impact, for papers by Benjamin M. Kagina Breakdown of academic impact, for papers by B. Ultsch
Rankless by CCL
2026